Singapore-based longevity innovation fund Immortal Dragons announced a strategic investment in Etheros Pharmaceuticals, a biotechnology firm focused on developing proprietary water-soluble fullerene-based catalytic antioxidant materials for aging-related scientific research. The investment aligns with Immortal Dragons’ mission to support technologies that expand understanding of aging mechanisms and related diseases.
Etheros is advancing a new class of water-soluble fullerene derivatives designed to act as catalytic antioxidants, which can continuously convert reactive oxygen species (ROS) into more stable molecules—a process known as catalytic dismutation. These compounds aim to overcome limitations of earlier antioxidant approaches by improving water solubility and performance for laboratory use.
Reactive oxygen species are by-products of metabolism and inflammation, and oxidative stress is widely studied as a contributor to biological aging and various chronic conditions. Etheros’ lead compound has shown catalytic activity for superoxide conversion comparable to other superoxide dismutase (SOD) mimetic materials under research, and early foundational studies have explored effects on oxidative stress markers, neurobiological pathways and neuroinflammation in animal models.
Immortal Dragons said the funding will support material optimization for research environments, analytical studies on catalytic performance, scaling research-grade manufacturing and development of analytical tools and biomarkers for laboratory models. Etheros’ materials are intended solely for scientific investigation and are not marketed as pharmaceuticals or clinical treatments at this stage.
The investment reflects broader interest in foundational aging science, particularly research into oxidative stress and its role in age-associated biological changes, with the goal of enabling deeper exploration of aging processes and disease mechanisms.
